Security key
N62509117
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)
CUSIP: N62509117
Q2 2023 13F Holders as of 30 Jun 2023
- Security type / class
- Equity / *W EXP 99/99/999
- Total 13F shares
- 1,884,490
- Total 13F value
- $3,937,717
- Share change
- -352,417
- SEC-reported price per share
- $2.09
- Number of holders
- 18
- Value change
- -$730,847
- Number of buys
- 3
- Number of sells
- 5
Report period
Q2 2023
Institutions
18
Top holders
10
NAMSW full security history
Ownership snapshot
Full 13F holder table
NewAmsterdam Pharma Co N.V. SEC filings
NewAmsterdam Pharma Co N.V. company facts
Broader feeds
Ownership snapshot
Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
0/15
Latest evidence
31 Mar 2023
13F
Highest disclosed value: $126,471,058
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Frazier Life Sciences Management, L.P. has the largest disclosed position value at $126.47M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Disclosed position value
Top 5
Frazier Life Sciences Management,...
$126.47M
Bain Capital Life Sciences Invest...
$110.24M
RA CAPITAL MANAGEMENT, L.P.
$53.65M
VIKING GLOBAL INVESTORS LP
$52.63M
DEERFIELD MANAGEMENT COMPANY, L.P.
$33.79M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. |
13F
Company
|
—
mixed-class rows
|
$126,471,058
9,841,884 shares
mixed-class rows
|
— | 31 Mar 2023 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
—
mixed-class rows
|
$110,242,000
8,400,000 shares
mixed-class rows
|
— | 31 Mar 2023 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
mixed-class rows
|
$53,653,333
4,333,333 shares
mixed-class rows
|
— | 31 Mar 2023 |
| VIKING GLOBAL INVESTORS LP |
13F
Company
|
—
denominator unverified
|
$52,629,293
3,915,870 shares
|
— | 31 Mar 2023 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
Company
|
—
mixed-class rows
|
$33,794,415
2,628,510 shares
mixed-class rows
|
— | 31 Mar 2023 |
| Medicxi Ventures Management (Jersey) Ltd |
13F
Company
|
—
denominator unverified
|
$26,520,000
2,000,000 shares
|
— | 31 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
1,884,490
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
18
Q2 2023 holders
18
Holder diff
0
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q2 2023 value | Value change | Value Chg % |
|---|